Evidence map›Paper›PMID 41111773›Full record

ArticleCureus2025

Trends in the Incidence of Rare Primary Cardiac Neoplasms: A Surveillance, Epidemiology, and End Results (SEER)-Based Analysis.

Joud K Alhousani, Ahmed Abdelmageed, Hamza Khoursheed, Said Yaseen, Mohammad Hamad, Hussam Askari, Leen Abu Rabi, Moh'd Taha, Abdulrahman Barakat, Abdulqadir J Nashwan

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joud K AlhousaniSchool of Medicine, Jordan University of Science and Technology, Irbid, JOR.
Ahmed AbdelmageedFaculty of Medicine, Mansoura University, Mansoura, EGY.
Hamza KhoursheedSchool of Medicine, Jordan University of Science and Technology, Irbid, JOR.
Said YaseenSchool of Medicine, Jordan University of Science and Technology, Irbid, JOR.
Mohammad HamadSchool of Medicine, University of Jordan, Amman, JOR.
Hussam AskariSchool of Medicine, Jordan University of Science and Technology, Irbid, JOR.
Leen Abu RabiSchool of Medicine, Jordan University of Science and Technology, Irbid, JOR.
Moh'd TahaSchool of Medicine, Jordan University of Science and Technology, Irbid, JOR.
Abdulrahman BarakatSchool of Medicine, Jordan University of Science and Technology, Irbid, JOR.
Abdulqadir J NashwanNursing and Midwifery Research Department, Hamad Medical Corporation, Doha, QAT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Primary malignant cardiac tumors (PMCTs) are considered extremely rare neoplasms, with limited population-level data on incidence patterns and future trends. This study aims to describe the epidemiology of PMCTs in the United States, focusing on three main histologic subtypes, such as sarcomas, lymphomas, and mesotheliomas, and to forecast incidence over the next decade. Methods We extracted cases of pathologically confirmed PMCTs diagnosed between 2000 and 2022 from the Surveillance, Epidemiology, and End Results (SEER) 17 Registries database. Incidence rates (IRs) were age-adjusted to the 2000 US Standard Population and stratified by histology, sex, age (<60 vs. ≥60 years), and race. Annual percent change and percentage change were calculated. Time series forecasting was performed using linear regression, ETS, ARIMA, and neural network autoregression models, with model selection based on root mean square error, mean absolute error, mean absolute percentage error, and residual diagnostics. Poisson and quasi-Poisson regression analyses evaluated demographic associations with incidence. Results From 2000 to 2022, PMCTs demonstrated distinct subtype-specific trends. Cardiac lymphoma incidence increased steadily, with forecasts predicting a rise from 0.062 per 100,000 in 2023 to 0.080 by 2032. Sarcoma incidence remained stable (~0.008-0.009 per 100,000) but was highly volatile year to year. Mesothelioma incidence was consistently low (<0.001 per 100,000) but projected to increase slightly over time. Age ≥60 years was strongly associated with higher sarcoma and mesothelioma incidence, whereas lymphoma showed no significant age-related difference. Sex and race disparities were evident: males had higher sarcoma and mesothelioma rates, while females had slightly higher lymphoma rates; Asian/Pacific Islander groups exhibited greater volatility in lymphoma incidence, and Black populations had the lowest incidence across subtypes. Conclusions PMCTs remain exceptionally rare, but incidence trends vary by histologic subtype. Cardiac lymphoma incidence is rising and expected to continue increasing, whereas sarcoma rates are stable, and mesotheliomas show a modest upward trajectory. These findings highlight the need for improved detection in high-risk groups, the integration of molecular data into registries, and the development of global cardiac tumor collaborations to refine epidemiologic understanding and improve patient care..

Indexed as

epidemiologyincidence trendspopulationprimary cardiac tumorsseer database

Identifiers

PMID41111773
PMCPMC12535152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.